HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 167 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $500,673,801 | +5.7% | 13,106,644 | -0.2% | 0.01% | +9.1% |
Q2 2023 | $473,825,079 | -8.2% | 13,136,265 | -2.8% | 0.01% | -15.4% |
Q1 2023 | $516,315,013 | -31.8% | 13,519,639 | +1.6% | 0.01% | -38.1% |
Q4 2022 | $756,988,895 | +43.6% | 13,303,847 | -0.2% | 0.02% | +31.2% |
Q3 2022 | $527,273,000 | -9.9% | 13,335,155 | +0.3% | 0.02% | 0.0% |
Q2 2022 | $585,061,000 | +10.7% | 13,296,813 | +0.4% | 0.02% | +33.3% |
Q1 2022 | $528,407,000 | -2.6% | 13,249,920 | -1.8% | 0.01% | 0.0% |
Q4 2021 | $542,670,000 | -2.1% | 13,495,913 | -1.0% | 0.01% | -14.3% |
Q3 2021 | $554,296,000 | -10.5% | 13,625,741 | -0.1% | 0.01% | -6.7% |
Q2 2021 | $619,315,000 | +12.0% | 13,638,304 | +2.9% | 0.02% | 0.0% |
Q1 2021 | $552,721,000 | -1.6% | 13,257,866 | +0.8% | 0.02% | -6.2% |
Q4 2020 | $561,625,000 | +67.9% | 13,149,703 | +3.3% | 0.02% | +45.5% |
Q3 2020 | $334,477,000 | -4.4% | 12,727,416 | -2.5% | 0.01% | -8.3% |
Q2 2020 | $349,806,000 | +39.9% | 13,047,599 | -6.1% | 0.01% | +9.1% |
Q1 2020 | $250,029,000 | +0.7% | 13,898,214 | -0.7% | 0.01% | +37.5% |
Q4 2019 | $248,277,000 | +12.5% | 14,003,155 | -1.6% | 0.01% | 0.0% |
Q3 2019 | $220,678,000 | -3.4% | 14,228,129 | +7.0% | 0.01% | -11.1% |
Q2 2019 | $228,442,000 | +5.0% | 13,296,940 | -1.6% | 0.01% | 0.0% |
Q1 2019 | $217,644,000 | +10.4% | 13,518,190 | +0.3% | 0.01% | 0.0% |
Q4 2018 | $197,093,000 | -18.5% | 13,471,918 | +1.2% | 0.01% | 0.0% |
Q3 2018 | $241,977,000 | +13.0% | 13,317,364 | +4.9% | 0.01% | 0.0% |
Q2 2018 | $214,161,000 | -9.1% | 12,694,846 | +5.6% | 0.01% | -10.0% |
Q1 2018 | $235,479,000 | +3.8% | 12,020,363 | +7.4% | 0.01% | 0.0% |
Q4 2017 | $226,844,000 | +30.7% | 11,196,595 | +12.1% | 0.01% | +25.0% |
Q3 2017 | $173,550,000 | +41.1% | 9,991,405 | +4.1% | 0.01% | +33.3% |
Q2 2017 | $123,010,000 | +8.3% | 9,595,212 | +9.5% | 0.01% | 0.0% |
Q1 2017 | $113,576,000 | +36.0% | 8,763,558 | +3.7% | 0.01% | +20.0% |
Q4 2016 | $83,509,000 | -15.7% | 8,452,343 | +3.1% | 0.01% | -16.7% |
Q3 2016 | $99,047,000 | +50.9% | 8,199,259 | +7.8% | 0.01% | +50.0% |
Q2 2016 | $65,658,000 | -8.0% | 7,608,228 | +0.9% | 0.00% | -20.0% |
Q1 2016 | $71,374,000 | -44.6% | 7,536,888 | +1.3% | 0.01% | -44.4% |
Q4 2015 | $128,938,000 | -72.1% | 7,440,205 | -67.4% | 0.01% | -47.1% |
Q3 2015 | $461,610,000 | +197.9% | 22,809,228 | +232.4% | 0.02% | +70.0% |
Q2 2015 | $154,961,000 | +64.5% | 6,862,761 | +4.0% | 0.01% | +66.7% |
Q1 2015 | $94,192,000 | +55.3% | 6,596,056 | +5.0% | 0.01% | +50.0% |
Q4 2014 | $60,647,000 | +6.4% | 6,284,638 | +0.4% | 0.00% | 0.0% |
Q3 2014 | $56,974,000 | -6.3% | 6,260,802 | +1.7% | 0.00% | -20.0% |
Q2 2014 | $60,816,000 | -22.2% | 6,155,526 | +0.1% | 0.01% | -28.6% |
Q1 2014 | $78,132,000 | -1.2% | 6,152,087 | +16.6% | 0.01% | 0.0% |
Q4 2013 | $79,072,000 | +40.2% | 5,275,026 | +3.3% | 0.01% | +16.7% |
Q3 2013 | $56,389,000 | +44.0% | 5,107,658 | +3.6% | 0.01% | +50.0% |
Q2 2013 | $39,148,000 | – | 4,930,482 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |